Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB has significantly expanded its share base following a rights issue completed in December 2025, increasing the total number of shares to 451,121,383, of which 448,671,220 are ordinary shares and 2,450,163 are class C shares, all together carrying 448,916,236 votes. The company’s share capital has risen to SEK 67,668,207.45 from SEK 17,192,695.20 after the rights issue and a previously resolved capital reduction, reinforcing Medivir’s financial structure and providing additional capital that can support its oncology-focused drug development strategy and strengthen its position on Nasdaq Stockholm’s Small Cap market.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish biotech company that develops innovative cancer drugs targeting areas with high unmet medical need, focusing on indications where existing therapies are limited or absent. Its lead candidate, fostroxacitabine bralpamide (fostrox), is designed to selectively treat cancer cells in the liver while minimizing side effects, and the company advances its pipeline both independently and through partnerships. Medivir’s shares are listed on Nasdaq Stockholm’s Small Cap list under the ticker MVIR.
Average Trading Volume: 1,164,677
Technical Sentiment Signal: Sell
Current Market Cap: SEK172.7M
For a thorough assessment of MVIR stock, go to TipRanks’ Stock Analysis page.